ERBB3 and neoplasm: Blocking hepatic uptake with DOTA-(Z08699)3 resulted in a tumor-to-liver ratio of 2.3 ± 0.5 at 24 h pi, which is the best value for HER3-targeting affibody molecules obtained in preclinical studies.